Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 9, 2011
Last updated: March 6, 2015
Last verified: March 2015
The aim of this study is to monitor any impact in the change from the lyophilised formulation to the liquid formulation of the Rotarix™ vaccine on hospitalisations for rotavirus gastroenteritis. This is planned to be assessed by comparing trends of hospitalisations due to laboratory confirmed rotavirus gastroenteritis in children <=5 years of age, before and after introduction of the liquid formulation of the vaccine in Belgium.

Condition Intervention
Infections, Rotavirus
Other: Data collection

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Retrospective
Official Title: Observational, Ecological, Database Study on Epidemiology of Hospitalisations With Rotavirus Gastroenteritis Confirmed in Children Aged ≤5 Years, and Any Impact in the Change From Lyophilised to Liquid Formulation of Rotarix™, in Belgium

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of rotavirus in hospitalised children aged ≤5 years during pre-introduction, introduction and post-introduction period of liquid formulation Rotarix™ [ Time Frame: up to 2 years post-introduction of liquid formulation of Rotarix™. ]

Secondary Outcome Measures:
  • Occurrence of rotavirus detected by laboratory tests in children of various age, gender and location (centre and region). [ Time Frame: up to 2 years post-introduction of liquid formulation of Rotarix™. ]
  • Occurrence of rotavirus detected by laboratory tests at a specific time (month and year). [ Time Frame: up to 2 years post-introduction of liquid formulation of Rotarix™. ]
  • Occurrence of rotavirus detected by various types of rotavirus laboratory tests. [ Time Frame: up to 2 years post-introduction of liquid formulation of Rotarix™. ]
  • Occurrence of rotavirus vaccination with a specific brand of vaccine (Rotarix and RotaTeq) among children ≤5 years of age in the Belgian population. [ Time Frame: up to 2 years post-introduction of liquid formulation of Rotarix™. ]

Enrollment: 1
Study Start Date: September 2011
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cohort A
Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
Other: Data collection
Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.


Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children hospitalised due to laboratory confirmed rotavirus gastroenteritis in approximately 8 hospitals across Belgium.

Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

  • Child aged ≤5 years with opportunity to receive lyophilised or liquid formulation of Rotarix™;
  • Hospitalised at one of the participating centres in Belgium;
  • A stool sample has been provided for a rotavirus detection test during the study period;
  • Laboratory test result of rotavirus is available.

Exclusion Criteria:

• None.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01435967

GSK Investigational Site
Antwerpen, Belgium, 2020
GSK Investigational Site
Bonheiden, Belgium, 2820
GSK Investigational Site
Charleroi, Belgium, 6000
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Hasselt, Belgium, 3500
GSK Investigational Site
Ieper, Belgium, 8900
GSK Investigational Site
Jette, Belgium, 1090
GSK Investigational Site
Yvoir, Belgium, 5330
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01435967     History of Changes
Other Study ID Numbers: 114061
Study First Received: September 9, 2011
Last Updated: March 6, 2015

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Rotavirus Infections
Gastrointestinal Diseases
Digestive System Diseases
Reoviridae Infections
RNA Virus Infections
Virus Diseases processed this record on April 28, 2017